Fig. 1: Study CONSORT Diagram. | npj Vaccines

Fig. 1: Study CONSORT Diagram.

From: Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

Fig. 1

Twenty-five healthy adults aged 18–70 years old enrolled between 8 October 2020 and 22 April 2021 to receive 20 mcg H10ssF once (n = 3) or 60 mcg H10ssF twice (n = 22) with an interval of 16 weeks between vaccines. A total of 7 early terminations resulted from participant relocation (n = 4), early withdrawal due to time commitment (n = 1), or loss of participant to follow-up (n = 2). All participants were monitored for safety and immunogenicity until study completion or termination.

Back to article page